secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001193125-23-071400
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics enters $75M at-the-market stock offering agreement with Jefferies
--------------------------------------------------------------------------------

- Company entered Open Market Sale Agreement with Jefferies LLC to sell up to $75M of common stock.
- Sales will be made 'at the market' under existing shelf registration statement (File No. 333-261019).
- Jefferies receives up to 3.0% commission on gross proceeds; company not obligated to sell any shares.
- Agreement terminates upon sale of all shares or earlier termination by either party.
- Proceeds intended for general corporate purposes and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312523071400/0001193125-23-071400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312523071400/d405925d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-071400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer